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Abstract
Taking into account that the imidazole ring has π-electron redundancy, con-
densed benzimidazole derivatives have attracted our attention as a promising 
class for the search for antioxidant substances. Synthesis was carried out, and 
information on the antioxidant activity of imidazo- and tetrahydropyrimido benz-
imidazoles was provided. Highly active antioxidant substance enoxifol has been 
revealed. The data on the synthesis and study of the pharmacodynamic, pharma-
cokinetic, and toxicological properties of the new antioxidant compound enoxifol 
are presented. The antioxidant activity of the compound is due to its ability to 
inactivate superoxide, hydroxyl, and peroxyl radicals, thereby reducing the overall 
oxidation rate due to a decrease in the total initiation rate. It has been shown that 
enoxifol has hepatoprotector, antihypoxic, cerebroprotective, nootropic, stress-
protective, neuropsychotropic, actoprotective, cardioprotective, antiaggregant, and 
antithrombogenic properties and is able to prevent rheological disorders in diabetes 
mellitus.
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1. Introduction
Currently, the fact that considered the leading role of free radical processes in 
the pathogenesis of more than 200 diseases has been established. Special attention 
is paid to damage to the brain tissue due to their particular sensitivity to disruption 
of oxygen balance and redox balance. The chain character of the reactions of lipid 
peroxidation (LPO) causes the appearance of a whole cascade of reactive oxygen 
forms, including superoxide, hydroxyl, and perhydroxyl radicals, singlet oxygen, 
hydrogen peroxide, and their active metabolites (nitrogen oxide, hypochlorite, 
etc.). The result is a violation of the integrity and permeability of the cell membrane 
and the destruction of proteins, lipids, carbohydrates, and nucleic acids, the cell 
genome suffers, and degenerative changes and neuron death develop. The processes 
of lipid peroxidation underlie most of the diseases of the central nervous system, 
which include acute and chronic disorders of cerebral blood circulation, degenera-
tive diseases of the brain and spinal cord, cancer pathology, etc. [1, 2].
Antioxidants, both endogenous and exogenous substances, limit LPO processes. 
Today, in practical health care, antioxidant preparations of natural origin and 
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synthetic compounds are used [3]. It should be noted that the group of drugs related 
to natural antioxidants has found quite wide application in clinical practice. At the 
same time, there is a clear shortage of synthetic antioxidant drugs. In view of the 
abovementioned, the emergence of a new effective antioxidant compound should 
arouse the interest of qualified specialists.
2. The results
A computer prediction of the antioxidant activity of new compounds was 
carried out in the “Microcosm” software [4], and the high predictive ability of 
the “Microcosm” information technology regarding the antioxidant activity of 
imidazo-benzimidazole derivatives has been demonstrated.
Condensed benzimidazole derivatives were synthesized, and experimental 
screening of the antioxidant activity of new chemical compounds was car-
ried out among the derivatives of 2-(hetaryl) imidazo[1,2-a]benzimidazoles 
(IMBI) [5], 3-aroyl- and 3-hetaroyl-IMBI [6], 2-methoxyphenyl-substituted 
9-dialkylaminoethyl-IMBI [7], 2-methoxy- phenyl- and 2-oxyphenyl-substituted 
1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives of 9H-2,3-dihydro-IMBI 
and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], 9-dialkylami-
noethyl-2-oxy(dioxy)phenyl-IMBI [10], aroylmethyl derivatives of tricyclic 
benzimidazole systems containing hydroxy groups in aroyl radicals [11], 3-(2,2,2-tri-
chloro-1-hydroxyethyl)-IMBI [12], 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 
1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], 9-R-2-halogenophenyl-IMBI 
[15], 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16], 
3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17], amides of 
2,3-dihydroimidazo- and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic 
acids [18], phenyl- and alkylthiocarbamides of 2,9-disubstituted IMBI [19], and 
1-substituted 2-benzylaminobenzimidazoles with phenyl methoxyls [20]. Butylated 
hydroxytoluene (BHT, CAS Number 128-37-0), also known as dibunol, was chosen 
as a comparative drug.
It was found that among the derivatives of 2-(hetaryl)-IMBI, high antioxidant 
activity superior to dibunol was shown by compounds containing in the second 
position of the tricycle such substituents as 1-methylbenzimidazolyl and 5-bro-
mothienyl. The remaining substances of this series showed an average level of activ-
ity, similar to or inferior to dibunol [5]. Among the 3-aroyl- and 3-hetaroyl-IMBI, 
no substances with antioxidant activity were found [6]. Among 2-methoxyphenyl-
substituted 9-dialkylaminoethyl-IMBI, 4-methoxy- and 3 methoxyphenyl-IMBI 
showed the greatest antioxidant effect, which was comparable to or exceeded 
dibunol [7]. Salts of the compounds 9-dialkylaminoethyl-IMBI with 3,4-dioxy-
phenyl substitute exhibited the greatest antioxidant activity that was twofold 
active than reference drug BHT. Compounds with 4- and 3-oxyphenyl substitutes 
or 2,4- and 2,5-dioxyphenyl substitutes, as a rule, laсked 3,4-dioxyphenyl-IMBI 
in activity; however they were similar in it to BHT [10]. Most of aroylmethyl 
derivatives of tricyclic benzimidazole systems containing hydroxy groups in aroyl 
radicals also proved to be highly active antioxidant substances that were superior 
to dibunol [11]. Derivatives of 9-R-2-halogenophenyl-IMBI had a pronounced 
inhibitory effect on the processes of lipid peroxidation comparable to dibunol [15]. 
The compounds from the series of 1-substituted 2-benzylaminobenzimidazoles 
with phenyl methoxyls acted similarly [20]. Amides of 2,3-dihydroimidazo- and 
2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids showed moderate 
AO activity compared to dibunol [18]. It was revealed that 2-methoxy-phenyl- and 
2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives 
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of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimid-
azoles [9], most of 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12] и 3-acetyl-2-R-
9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], 
and 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17] showed 
the weak antioxidant activity compared to the reference drug. Among 10-alkylami-
noethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16] and phenyl- and 
alkylthiocarbamides of 2,9-disubstituted IMBI [19], antioxidant action has not been 
found.
As a result of previous investigations, the 2-(3,4-dihydroxyphenyl)-9-diethyl-
aminoethyl-imidazo [1,2-a]benzimidazole derivative of dihydrobromide (RU-185, 
enoxifol) was identified as an antioxidant compound with antiradical and mem-
brane-protective properties [21, 22], having multicomponent mechanisms of action 
and a wide range of pharmacodynamic effects. For enoxifol, a cardioprotective 
effect and a positive effect on the microcirculation of blood vessels are characteris-
tic. Antioxidant compound reduces platelet aggregation [23–25], reduces increased 
blood viscosity, and increases red blood cell deformability [26]. Preclinical toxicol-




benzimidazole dihydrobromide (RU-185) starts from saponification of benzimid-
azole-2-carbamic acid methyl ester under alkaline conditions to obtain 2-amino-
benzimidazole. Subsequent alkylation in acetone in the presence of alkali with 
N,N-diethylaminoethyl chloride formed by the action of thionyl chloride on N,N-
diethylaminoethanol and condensation with a 3,4-dimetoxiphenacylbromide or or 
3,4-dioxiphenacyl chloride, followed by intermolecular cyclization in 48% hydro-
bromic acid (boiling temperature 127°C) under reflux, afforded target compound 
RU-185.
2.1.1 Stage 1: preparation of 2-aminobenzimidazole
2-Aminobenzimidazole is obtained by saponification of benzimidazole-2-car-
bamic acid methyl ester (BMС-2) in aqueous solution of sodium hydroxide. The 
yield of 2-aminobenzimidazole is 65–75%. At the next stage, 2-aminobenzimidazole 
is used with a melting point of 223–232°С (within 2 degrees). If necessary, the 
amine is purified by crystallization from water and acetone or by precipitation from 
an aqueous hydrochloric acid solution.
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2.1.2 Stage 2: preparation of diethylaminoethyl chloride hydrochloride
Diethylaminoethyl chloride hydrochloride is obtained by chlorination of 
diethylaminoethanol with thionyl chloride in toluene or benzene. Purification can 
be performed by distillation at atmospheric pressure, collecting the fraction with 
161–162°C boiling point.
Diethylaminoethanol was distilled in case of poor quality and dried over anhy-
drous potassium carbonate (1:10 w/v) prior to use. After standing for 6–8 hours 
with periodic stirring, the desiccant was filtered off. Thionyl chloride (technical) 
was also distilled at atmospheric pressure before use (boiling point 74–75°C).
2.1.3 Stage 3: synthesis of 2-amino-1-diethylaminoethylbenzimidazole
2-Amino-1-diethylaminoethylbenzimidazole is obtained by alkylation of 
2-aminobenzimidazole with N,N-diethylaminoethyl chloride in acetone in a pres-
ence of a concentrated alkali solution. Upon completion of the reaction, the acetone 
is distilled off at atmospheric pressure and can be used at the same stage without 
further purification. Water is added to the residue, and the precipitate of the alkyl-
ated amine is filtered off to give 82–88% yield.
2.1.4  Stage 4: 2-(3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo[1,2-a]benzimidazole  
dihydrobromide (RU-185)
Synthesis of compound RU-185 is achieved by treatment of 2-amino-1-diethylami-
noethylbenzimidazole with α-chloro-3,4-dihydroxyacetophenone [28] (Method A)  
or with 3,4-dimethoxyphenacyl bromide. Subsequent cyclization of the formed 
quaternary 2-aminobenzimidazole salts is achieved in concentrated HBr (Method B).
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Method A The method consists of boiling of 1-diethylaminoethyl-2-ami-
nobenzimidazole and α-chloroacetopyrocatechol in dry acetonitrile until the 
quaternization reaction is complete (2–3 hours with TLC control). Then the solvent 
is evaporated to dryness, and concentrated HBr is added followed by reflux for 
1–2 hours. Reaction mixture is left overnight in the refrigerator. The next day, the 
precipitate formed (large needles) is filtered off. The yield of dihydrobromide (I) is 
97%. Recrystallization of the crude product from 80% aqueous ethanol with addi-
tion of activated charcoal affords white crystals with a yield of 85%. The product 
should be protected from direct sunlight. After drying at 110–120°C, the melting 
point of dihydrobromide is 289–290°C (decomposition).
Method B 3,4-Dimethoxyphenacyl bromide is added to a hot solution of 
2-amino-1-diethylaminoethylbenzimidazole in acetone (molar ratio 1:1). Next, the 
mixture is kept for 6–8 hours at room temperature. The precipitate of 2-amino-(3,4-
dimethoxyphenacyl)-1-diethylaminoethylbenzimidazolium bromide is filtered off. 
The output is 93.5% and melting point 182°C (decomposition, from ethanol).
Next, the resulting bromide is refluxed in conc. HBr (127°C) for 6–8 hours, while 
as the boiling of the initially formed solution precipitates. After cooling, it is filtered 
off, washed with acetone, and air dried. The yield is 96%. Crystallization from 80% 
aqueous ethanol gives (3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo[1,2-a]
benzimidazole dihydrobromide (I) identical to the product described in method A.
2.2 Pharmacological properties
2.2.1 Antioxidant activity
For several years, the ability of compounds to inhibit oxidative processes in 
the cells of various tissues, organs, and biological fluids has been thoroughly 
investigated. The study of the antioxidant properties of enoxifol was carried out 
by several methods: ascorbate-induced LPO according to the method [29], Fe2+-
induced chemiluminescence (CL) of lipids [30], and NADPH-dependent LPO [31]. 
Superoxide dismutase-like activity has been studied in a quercetin oxidation model 
[32], interaction with the free radical of 2,2-diphenyl-1-picrylhydrazyl (DPPH*) 
according to the method [33], and interaction with reactive oxygen species on 
the luminol-dependent CL model [34], the ability to inactivate the superoxide 
anion radical was estimated by the xanthine-xanthine oxidase-induced lucigenin-
dependent CL method [2], and the ability of substances to intercept and inactivate 
the peroxyl radical was determined by the ABAP-induced CL method [35]. The 
spectrum of antioxidant activity of enoxifol and the reference compound trolox is 
shown on Figure 1. It was found that enoxifol can react with lipid peroxyl radicals 
Figure 1. 
Antioxidant activity spectrum of enoxifol (A) and trolox (B) (−Lg IC50 (М)).
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at the chain termination stage, as indirectly evidenced by its high inhibitory activity 
during ascorbate, NADPH-induced lipid peroxidation, and CL of lipids, as well as 
directly inactivate superoxide, hydroxyl, and peroxyl radicals that initiate oxida-
tion, as demonstrated in reactions with the free radical DPPH, quercetin oxidation, 
Fe2+-induced CL in the presence of luminol, xanthine-xanthine oxidase induced 
by lucigenin-dependent CL, as well as thermal decomposition of the water-soluble 
compound 2,2-azobis (2-methylpropionamidine) dihydrochloride (ABAP) with the 
release of peroxyl radicals, inactivating free radicals and enoxifol, thereby reducing 
the overall oxidation rate by reducing the total initiation rate [35, 36].
As a result of the analysis of the chemical structure of enoxifol, the structural 
descriptors were determined, allowing the compound to exhibit antioxidant and 
antiradical activities. The molecule of enoxifol can manifest these properties due to 
a fragment of 3,4-dihydroxyphenyl and π-electronic redundancy of the imidazole 
ring in the structure of imidazobenzimidazoles [37]. Given the relatively low toxic-
ity and high antioxidant potential, the compound was selected for in-depth study 
on pathological models.
2.2.2 Membranoprotective properties
Membranoprotective activity of enoxifol was studied using the model [38], deter-
mining the mechanical strength and resistance of erythrocyte membranes to the 
hypoosmotic HCl solution. The membrane-stabilizing activity of the compound 
(inhibition of slow and fast incoming transmembrane ion currents) has been 
revealed. An effective dose of a compound of 20.5 mg/kg has been established [39].
2.2.3 Hepatoprotective effects
When studying the hepatoprotective properties of enoxifol with a 3-day prophy-
lactic administration in dose 2.25 mg/kg on a model of acute tetrachloromethane 
hepatitis, it was found that enoxifol significantly improved the absorption and 
excretory function of the liver and its detoxification abilities Under its influence the 
development of signs of the cytolytic, hepatodepressive, mesenchymal-inflamma-
tory, and cholestatic syndrome was significantly inhibited, surpassing tocopherol 
acetate in effectiveness [40].
2.2.4 Antihypoxic action
The antihypoxic properties of enoxifol have been studied in several models of 
hypobaric, hemic, and tissue hypoxia. In particular, the activity of the compound 
was established during intrauterine hypoxia and during recovery after acute 
hypobaric hypoxia. The potential protective effect of the antioxidant compound in 
hypobaric hypoxia was determined in high- and low-resistant to hypoxia animals in 
a flow-type pressure chamber at the “height” of 12,500 and 11,000 m, respectively 
[41]. The most effective doses in these models were 3 and 5 mg/kg [42]. Enoxifol 
showed a protective effect in modeling intrauterine hypoxia in dose 10 mg/kg dur-
ing course administration [42].
The activity of the compound in the recovery period after acute hypobaric 
hypoxia was determined by the change in behavioral reactions, cognitive functions, 
and the physical condition of the animals. The protective dose of enoxifol was 5 mg/kg. 
Tissue and hemic hypoxias were created by injecting potassium cyanide and sodium 
nitrite, respectively [43]. The protective action of enoxifol was judged by the degree 
of survival of the animals. The range of effective doses was determined from 0.5 to 
5 mg/kg [44].
7Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents’ Search and Development
DOI: http://dx.doi.org/10.5772/intechopen.82817
2.2.5 Cerebroprotective properties
The cerebroprotective effect of enoxifol was established on two models of 
cerebral ischemia of two and four vascular ligature of the carotid and paravertebral 
arteries, respectively, as well as during the reperfusion period [25, 44]. Antioxidant 
compound significantly increased the survival rate of animals, decreased blood 
viscosity by reducing platelet and red blood cell (RBC) aggregation and improv-
ing the mechanical properties of RBC, and corrected the behavioral deficit in the 
postischemic period. Doses of enoxifol in which the cerebroprotective activity was 
established were 5 and 10 mg/kg.
2.2.6 Nootropic activity
Nootropic activity of enoxifol was established in the model of the conditioned 
passive avoidance reaction, which allows to evaluate the effect of a studied com-
pounds on learning and memory. As a result, it was found that enoxifol influenced 
the ability of animals to consolidate information, reduced the deficit in the repro-
duction of a memorable trace, and intensified the input and initial processing of 
information in dose 10 mg/kg. The study of the enoxifol effect on the research 
behavior and emotionality of animals was carried out in the open-field modified 
test that allows to evaluate the nonassociative behavior of animals in familiar sur-
roundings. Against the background of a 3-day course of administration of the anti-
oxidant compound in dose of 10 mg/kg, psycho-emotional reactivity and anxiety in 
animals were decreased. With repeated testing, the memories of the arena research 
were better preserved. Experiments conducted in a Morris maze test confirmed 
the potential ability of enoxifol in a similar dose to increase mnestic abilities and 
improve the spatial orientation of animals [45].
2.2.7 Stress-protective effects
The stress-protective effect of enoxifol was studied on models of short-term 
(1 hour) and prolonged (48 hours) hypokinetic stress [46] and hyperkinetic stress 
with the paradoxical sleep phase deprivation in rats, in the test of slowly rotat-
ing rod [47]. Enoxifol was administered to animals in doses 5 and 10 mg/kg. An 
antioxidant compound showed an ambiguous therapeutic effect depending on the 
experimental model used. The antioxidant was not effective in the short-term hypo-
kinetic stress technique. Enoxifol reduced post-stress injuries of internal organs 
and corrected the targeted behavior of animals in prolonged hypokinetic stress. 
Enoxifol did not affect the behavioral activity of rats but protected internal organs 
from pathological abnormalities in hyperkinetic stress [37].
2.2.8 Actoprotective activity
The effect of enoxifol on physical performance and recovery period after 
physical exertion was studied under normal and complicated conditions in several 
experimental models. We used the swim to the limit test [48], fatigue development 
test [49], and efficiency test in anti-orthostatic condition [50]; the model allows 
to study the recovery process after exercises [51] and the method of research of 
animals’ endurance to training and exhausting loads [49]. Actoprotective proper-
ties were studied in models associated with limiting physical loads (swimming 
to failure), with the rate of fatigue development, and in the test of swimming in 
complicated anti-orthostatic condition. Enoxifol increased the duration of physical 
performance under normal and complicated conditions, stabilized some indicators 
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of energy metabolism (the level of lactate, glycogen, tryptophan, the ratio of pyru-
vate and lactate), normalized indicators of lipid peroxidation, and had a protective 
effect on the myocardium of animals during the period of exhaustive physical 
activity. A number of effective doses amounted to 1, 3, 5, 10, 20, 25, and 50 mg/kg 
in various physical activity tests [52].
2.2.9 Cardioprotective properties
Cardioprotective activity was studied in isolated atrial rhythm disturbances 
induced by hydrogen peroxide oxidation [53], in postischemic reperfusion fibrillations 
of the heart ventricles [54], in the technique of rhythm disturbances caused by calcium 
chloride and adrenaline intoxication [55], and in the myocardial ischemia provoked 
by coronary occlusion [31] and the experimental myocardial infarction method [56]. 
As a result it was found that enoxifol exerted an antiarrhythmic effect, increasing the 
resistance of cardiomyocyte membranes to LPO products. The compound increased 
the stability of the myocardium of animals having a non-antioxidant diet to calcium 
chloride cardiac arrhythmias and increased myocardial tolerance to ischemia. Enoxifol 
completely prevented ventricular fibrillation of the heart in postischemic myocardial 
reperfusion. It reduced the extrasystole severity and ventricular fibrillation and 
reduced the death of animals in the model of coronary artery occlusion and systemic 
peroxidation syndrome. The novel compound limited area of necrosis in experimental 
myocardial infarction. It showed activity in doses 7.9, 14, and 20.5 mg/kg [39, 55].
2.2.10 Antithrombotic and antiaggregant effects
Enoxifol had a pronounced antithrombotic effect in arterial thrombosis models 
induced by application of ferric chloride and electric current on the rat carotid 
artery and blocked platelet aggregation caused by ADP, collagen, adrenaline, 
arachidonic acid, thrombin, and an agonist of thromboxane receptors U46619 [24]. 
The antioxidant compound reduced levels of proaggregant and vasoconstrictor 
ТХА2, which was confirmed by a decreased level of MDA in the ex vivo pathology 
caused by thrombin, and decreased the level of total and membrane-bound calcium 
in platelets, inhibiting calmodulin-dependent PDE cAMP.
2.2.11 Action on hemorheology
The study of the enoxifol action on hemorheology was carried out in the model 
of “increased viscosity syndrome” according to the method [57]. An improvement in 
blood flow, membrane plasticity, and inhibition of erythrocyte aggregation under the 
influence of enoxifol administration in dose 5 mg/kg was found [18]. An increase in 
the rate of local cerebral blood flow and a direct effect on the tone of cerebral vessels 
in a similar dose were determined in the method of tissue microcirculation [58]. The 
study of the enoxifol effect on hemorheology in models of severe forms of streptozoto-
cin diabetes was also performed. Antioxidant compound corrected hemobiological 
parameters (aggregation, deformability, mechanical properties of erythrocytes), 
almost normalized indicators of lipid peroxidation, reducing the products of peroxida-
tion, and increased the activity of antioxidant enzymes. The effective dose was 5 mg/kg  
for the course of the 3-day administration preliminary to diabetes modeling [58].
2.2.12 Pharmacokinetic profile
In the study of the pharmacokinetic properties of enoxifol [27], determina-
tion was carried out for 12 hours in the blood and internal organs and in the 
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urine and feces within 48 hours. It was found that the absolute bioavailability of 
unchanged enoxifol was 30% and for the total amount of enoxifol and its active 
metabolites, 99%. When administered orally, enoxifol was well absorbed from 
the gastrointestinal tract, the maximum concentration in the blood was observed 
after 1 hour, and after 7 hours the compound was not detected. The excretion 
of the compound occurs mainly through the intestines, and only one-fifth is 
excreted unchanged; a small amount of enoxifol is excreted through the kidneys. 
The half-life for enoxifol was 1.43 hours. After the intravenous administration, 
the maximum concentration of the compound in the blood is determined in 
10 minutes; after 7 hours the antioxidant in the blood was not recorded. The 
excretion of the infusion form of enoxifol occurs mainly through the kidneys in 
the unchanged form. In a much smaller amount, enoxifol was eliminated with 
feces. The half-life was 0.78 hours [27].
2.2.13 Toxicological properties
A study of the drug safety of enoxifol [59] found that the antioxidant compound 
can be attributed to low-toxic substances. The acute toxicity of enoxifol after oral 
administration was 1792.56 mg/kg for male and 2260.28 mg/kg for female rats. 
When administered intravenously, the LD50 was determined for male in dose 
109.20 mg/kg and for female rats in dose 126.04 mg/kg. Chronic administration in 
therapeutic doses (5–25 mg/kg) showed that toxic effects in the central nervous sys-
tem, liver function, kidney function, and the generative system were not observed. 
In the high dose (200 mg/kg), slight deviations in the behavioral responses of ani-
mals and a slight decrease in the detoxification function of the liver were observed. 
The accumulation ability of enoxifol wasn’t found [59].
3. Conclusion
Summarizing the data obtained, we can conclude that condensed benzimidazole 
derivatives with π-electron redundancy are a new scaffold for searching antioxidant 
substances. The highest amount of compounds with high antioxidant activity was 
found in derivatives of 2-(hetaryl)-aroylmethyl-, and 9-dialkylaminoethyl-IMBI, 
with oxy- and dioxyphenyl substitutes especially.
The revealed compound enoxifol from the 9-dialkylaminoethyl-IMBI series 
exhibits pronounced antioxidant, hepatoprotective, antihypoxic, cerebroprotec-
tive, nootropic, stress-protective, neuropsychotropic, actoprotective, cardio-
protective, antithrombogenic and hemorheological properties. Pharmacokinetic 
parameters of enoxifol were established, and general and specific toxicities were 
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